CLDX Q1 2018 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+165.2% YoY

Gross Profit

-$18M-437.7% margin

Operating Income

-$120M-2941.9% margin

Net Income

-$118M-2903.9% margin

EPS (Diluted)

$-12.61

QoQ Revenue Growth

+17.7%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$28M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$191M

Total Liabilities

$57M

Stockholders' Equity

$134M

Cash & Equivalents

$40M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$2M	+165.2%
Gross Profit	-$18M	-$24M	+26.6%
Operating Income	-$120M	-$35M	-240.8%
Net Income	-$118M	-$34M	-244.8%

Revenue Segments

Contracts And Grants

$3M76%

Product Development And Licensing Agreements

$992,00024%